HFSA will host Understanding and Managing ATTR Amyloidosis webinar on Wednesday, October 22, 2025 from 6:00 – 6:45 PM ET. This HFSA Patient & Caregiver webinar will provide a foundational overview of ATTR amyloidosis, including the differences between hereditary and wild-type forms. Participants will learn to recognize key symptoms, understand the importance of early diagnosis, and explore current treatment options and emerging therapies. View the program agenda below.
Program Agenda*
All sessions are listed in Eastern Time.
Welcome, Opening Remarks, and Introductions
Sharon Huerta, APRN, HFSA Patient Committee
Baptist Memorial Hospital – Memphis
- Introduction of Topic
- Acknowledgement of sponsors
Understanding ATTR Amyloidosis
Andres Carmona Rubio, MD
Cleveland Clinic - Heart Failure & Cardiac Transplantation & Amyloidosis Center
- What is ATTR Amyloidosis?
- Types: Hereditary vs. Wild-Type
- Causes, Risk Factors & Genetic Considerations
Signs, Symptoms, & Diagnosis
Andres Carmona Rubio, MD
Cleveland Clinic - Heart Failure & Cardiac Transplantation & Amyloidosis Center
- Common Symptoms & Progression
- Diagnostic Tools & Biomarkers
- Importance of Early Detection
Treatment Options & Emerging Therapies
Tolulope Adesiyun, MD, FACC
Virtua Health - Medical Director Advanced
- FDA-Approved Treatments & Their Mechanisms
- Clinical Trials & Future Therapies
Patient Perspective
Sean Riley
Patient Advocate and HFSA Patient Committee Member
- Real-World Patient Experience
- Challenges & Management Strategie
Q&A Segment – Provider and Patient will engage in question-and-answer segment with attendees
Closing Remarks
Visit Sponsor and Participating Patient and Provider Group Resource Pages
Attendees are encouraged to visit resource pages for additional information and helpful resources.